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Background: Myxoid liposarcoma is a mesenchymal malignancy most commonly presenting in young adults. This
tumor is known for its characteristic chromosomal rearrangement at the DDIT3 locus.
Results: We report a case of myxoid liposarcoma in a 91-year-old, the oldest known patient with this disease-entity.
FISH analysis of the DDIT3 and FUS loci demonstrate the pathognomonic chromosomal alteration in the setting of
predominantly round cell histology on biopsy, confirmed by RT-PCR.
Conclusion: Myxoid liposarcoma affects mostly young adults but can be seen in the elderly population. Molecular and
cytogenetic assays are helpful auxiliaries to histology in the setting of unusual histology and clinical presentation.
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Myxoid liposarcoma, the second-most common subtype of
liposarcoma, accounts for 10% of soft tissue sarcomas [1].
Myxoid liposarcoma tends to occur on extremities, with
two thirds of cases originating in the thigh [2]. This disease
affects a younger demographic than most cancers with peak
incidence between ages 30–50 [1], and is the most common
subtype of liposarcoma in the pediatric age group [3].
Typical myxoid liposarcoma histology shows nonpleo-
morphic ovoid mesenchymal cells and rare lipoblasts
amidst a prominent myxoid stroma, with an intricately
plexiform vasculature. Round-cell liposarcoma, a high-
grade form of myxoid liposarcoma, lacks myxoid matrix
leaving closely packed, round mesenchymal cells. Regions
of myxoid and round-cell liposarcoma morphologies often
coexist (MLS/RCLS).
Both morphologies share identical cytogenetic aber-
rations and are thus considered as a single pathologic
entity [1]. A reciprocal translocation t(12;16) can be
identified in the majority of cases [4] creating an in-frame
fusion of FUS and DDIT3 that is specific for MLS/RCLS
[5]. A small proportion of cases harbor an alternate
t(12;22) EWS-DDIT3 rearrangement [6]. Demonstration
of disruption at the DDIT3 locus is an effective diagnostic
tool for MLS/RCLS [7], with break-apart fluorescent
in situ hybridization (FISH) probes commercially available.
The most powerful prognostic marker in MLS/RCLS is
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distribution, and reproduction in any mediumthan 5% of the tumor. These high grade round cell liposar-
caromas have been shown to behave more aggressively with
decreased overall survival and metastasis free survival [8].
Compared with other soft tissue sarcomas, MLS/RCLS
is particularly sensitive to radiation therapy [9]. Accordingly,
neoadjuvant radiation has been recommended in the
treatment of myxoid liposarcoma [10]. This finding
places increased significance on accurate diagnosis prior
to surgical resection.
The following report depicts a case of MLS/RCLS in
a rare elderly age demographic while highlighting the
salient diagnostic features of this disease, and the value
of molecular testing in the context of unusual clinical
features and histology.
Case presentation
A 91-year-old male presented to a local emergency depart-
ment complaining of a large mass in the medial thigh that
had grown in size over the preceding several weeks. The
mass was otherwise asymptomatic.
The patient’s past medical history included atrial fibrilla-
tion and hypertension, prostate cancer treated by resec-
tion with local recurrence treated by radiotherapy 20 years
previously, laryngeal cancer treated by radiotherapy 14 years
previously, and finally, separate histories of both colon and
anal cancer treated with an abdominal-perineal resection
6 years previously. The patient reported a family history of
ovarian cancer and multiple prostate cancers.
CT scan of the pelvis demonstrated a 19 cm lobulated
mass with complex septations and central necrosis in
the adductor compartment of the left thigh (Figure 1).Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Abdomino-pelvic CT scan showing tumor in the left
medial thigh (*).
Figure 2 Core needle biopsy of mass. (a) 20× H&E section showing h
(c) Fluorescent photomicrographs showing biopsied tumor cells hybridi
FUS (c) loci. Probes flank targeted gene sequence showing yellow signa
and or green signals when bound in isolation (rearranged locus). EWSR1
per nucleus.
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ance showed high-grade spindled, ovoid and round cell
morphology. Although a small amount of myxoid matrix
and complex vasculature were noted, no unequivocal
lipoblasts were evident and the tumor was considered to
lack differentiation towards any specific lineage (Figure 2a).
Immunohistochemical workup was nonspecific, with
the tumor showing positive staining for S-100 and weak
staining for CD34 and BCL-2. No immunoreactivity was
present for melan-A, pankeratin, desmin, smooth-muscle
actin, TLE, CD20, CD43, or CD99. Mitotic figures were
numerous and the Ki67 index was high. With no specific
diagnosis evident after this workup, in the context of blue
cell histology for a large soft tissue mass, FISH analysis
was performed for DDIT3, FUS¸ and EWSR1. Break-apart
probes for DDIT3 and FUS demonstrated chromosomal
rearrangements at both of these loci (Figures 2b, c),
while EWSR1 was intact. RT-PCR confirmed expression
of a type 1 FUSexon7-DDIT3exon2 fusion transcript.
The RT-PCR was performed according to previously
established protocols [11], using oligonucleotide primers
to exon 6 of FUS (5′-gaacccagaggtcgtggag-3′) and exon 2
of DDIT3 (5′-tgctttcaggtgtggtgatg-3′).
Based on the pathognomonic molecular findings, a
diagnosis of MLS/RCLS was made. The patient was
discussed at multidisciplinary tumor board, and of-
fered neoadjuvant radiation treatment followed by
surgical excision. Both radiation and surgery were well-
tolerated. Final pathology showed a 19 cm lobulated
heterogenous yellow and hemorrhagic mass (Figure 3a).
Microscopic sections showed a mixture of high-grade
round cell areas similar to that seen at biopsy, as well as re-
gions showing a more typical myxoid liposarcoma histology
that had not been evident on the core biopsy (Figures 3b, c),
providing morphological confirmation of the diagnosis.ypercellularity, and lacking any differentiated morphology. (b) and
zed to commercial break-apart probes specific to the DDIT3 (b) and
l when bound in proximity (intact locus) and showing individual red
(not shown) was conversely intact with two paired (yellow) signals
Figure 3 Excision of mass. Gross photo showing 19 cm yellow, hemorrhagic mass (a), featuring regions with typical myxoid liposarcoma,
10× H&E (b), and typical chicken-wire vasculature highlighted by CD31 immunohistochemical stain (c).
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reports of myxoid and/or round cell liposarcoma in the
elderly. Moreau et al. [10] recently published a series of
418 MLS/RCLS patients, the oldest being 85 years old at
presentation. To our knowledge, the current case repre-
sents the oldest reported age for a patient presenting with
primary myxoid or round cell liposarcoma.Discussion
Several facets of myxoid liposarcoma diagnosis and
treatment are highlighted in this case. The diagnosis of
myxoid liposarcoma in an elderly patient is uncommon,
but does occur. Thus an advanced age should not ex-
clude myxoid liposarcoma when other clinical, radio-
logic, histologic, or molecular findings support this
diagnosis.
Myxoid liposarcoma can show a wide variation of
histologic patterns, at times within the same tumor [12].
This can lead to difficult diagnoses, especially on small
biopsy specimens. This case highlights the value of mo-
lecular diagnosis as an adjunct to histology. FISH is
available in specialty centers, and is available to most
surgical pathology labs as it can be performed on stand-
ard formalin-fixed, paraffin-embedded tissue sections
(shipped to central labs if needed). In the current era of
diagnostics, molecular confirmation of sarcomas is
quickly becoming a standard of care for several types
of sarcomas bearing pathognomonic genetic events.
The availability of molecular diagnostic tools may, in
part, contribute to the overall improved outcomes ob-
served in sarcoma patients treated at higher volume
institutions [13].
The accurate preoperative diagnosis of myxoid lipo-
sarcoma prioritized neoadjuvant radiotherapy as the
next step in management. This treatment modality has
particular benefit in myxoid liposarcoma [9]. Accurate
diagnosis on biopsy in elderly patients may haveadditional value if poor baseline functioning precludes
the patient as a surgical candidate, as palliative radi-
ation may be particularly effective after a diagnosis of
myxoid liposarcoma.Conclusion
Myxoid/round cell liposarcoma is a relatively common
sarcoma among younger adults presenting with a large,
deep-seated malignant primary soft tissue mass. However,
this tumor can affect older individuals. Molecular cyto-
genetic studies can greatly assist diagnosis in cases with
unusual clinical and histologic features.Consent
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